Stefanie Schatz

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 9

Top Topics

Radiation Therapy

Cross Sectional

Small Cell Lung Cancer

Top Venues

Current oncology (Toronto, Ont.)

This page only lists publications with an associated author ORCID identifier.

Publications

Markus Falk, Eva Willing, Stefanie Schmidt, Stefanie Schatz, Marco Galster, Markus Tiemann, Joachim H Ficker, Wolfgang M Brückl
Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Current oncology (Toronto, Ont.) 30 (2) (2023)
Eva Maria Willing, Claudia Vollbrecht, Christine Vössing, Peggy Weist, Simon Schallenberg, Johanna M Herbst, Stefanie Schatz, Balázs Jóri, Guillaume Bataillon, Philipp Harter, Vanda Salutari, Antonio Gonzáles Martin, Ignace Vergote, Nicoletta Colombo, Julia Roeper, Tobias Berg, Regina Berger, Bettina Kah, Trine Jakobi Noettrup, Markus Falk, Kathrin Arndt, Andreas Polten, Isabelle L Ray-Coquard, Franziska Selzam, Judith Pirngruber, Stefanie Schmidt, Michael Hummel, Markus Tiemann, David Horst, Jalid Sehouli, Eric Pujade-Lauraine, Katharina Tiemann, Elena Ioana Braicu, Lukas C Heukamp
Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation. Cancers 15 (13) (2023)
Markus Falk, Eva Willing, Stefanie Schmidt, Stefanie Schatz, Marco Galster, Markus Tiemann, Joachim H Ficker, Wolfgang M Brückl
Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Current oncology (Toronto, Ont.) 30 (2) (2023)
Markus Falk, Eva Willing, Stefanie Schmidt, Stefanie Schatz, Marco Galster, Markus Tiemann, Joachim H Ficker, Wolfgang M Brückl
Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Current oncology (Toronto, Ont.) 30 (2) (2023)
Markus Falk, Eva Willing, Stefanie Schmidt, Stefanie Schatz, Marco Galster, Markus Tiemann, Joachim H Ficker, Wolfgang M Brückl
Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Current oncology (Toronto, Ont.) 30 (2) (2023)
Markus Falk, Eva Willing, Stefanie Schmidt, Stefanie Schatz, Marco Galster, Markus Tiemann, Joachim H Ficker, Wolfgang M Brückl
Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Current oncology (Toronto, Ont.) 30 (2) (2023)
Markus Falk, Stefanie Schatz, Fabian P M Reich, Stefanie Schmidt, Marco Galster, Markus Tiemann, Joachim H Ficker, Wolfgang M Brückl
Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report. Current oncology (Toronto, Ont.) 30 (10) (2023)
Markus Falk, Eva Willing, Stefanie Schmidt, Stefanie Schatz, Marco Galster, Markus Tiemann, Joachim H Ficker, Wolfgang M Brückl
Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Current oncology (Toronto, Ont.) 30 (2) (2023)
Balázs Jóri, Stefanie Schatz, Len Kaller, Bettina Kah, Julia Roeper, Hayat O Ramdani, Linda Diehl, Petra Hoffknecht, Christian Grohé, Frank Griesinger, Markus Tiemann, Lukas C Heukamp, Markus Falk
Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy. Cancers 13 (12) (2021)